Ketogenic Diet for Infantile Spasms
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether a ketogenic diet, high in fats and low in carbohydrates and proteins, can help prevent epileptic spasms in infants with genetic seizure disorders. Untreated epileptic spasms can worsen developmental outcomes. The trial targets infants diagnosed with epilepsy before six months of age who exhibit abnormal development or neurological issues, such as vision problems or muscle tone abnormalities. Participants will follow a specific ketogenic diet formula to assess its safety and effectiveness. As a Phase 1 trial, the research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new dietary intervention.
Will I have to stop taking my current medications?
You may need to stop taking certain medications like vigabatrin, ACTH, corticosteroids, topiramate, or zonisamide, as they are not allowed in the trial. However, other anti-seizure medications are permitted.
What prior data suggests that this protocol is safe for infants?
Research has shown that the ketogenic diet is generally safe for children with epilepsy, including those with infantile spasms, a type of seizure. Studies have found that it can greatly reduce seizures and sometimes even stop them completely.
A recent study discovered that the ketogenic diet causes fewer and less severe side effects than ACTH, a common treatment for infantile spasms. This suggests it might be a gentler way to manage seizures.
Overall, the ketogenic diet has a strong safety record for treating seizures. Side effects can occur, but they are usually mild and happen less often than with some other treatments.12345Why are researchers excited about this trial?
Unlike traditional treatments for infantile spasms, which often include medications like ACTH or Vigabatrin, the ketogenic diet offers a unique approach by altering the body's metabolism. Researchers are excited about this treatment because it provides a non-pharmacological option, potentially reducing the side effects associated with medications. The diet works by shifting the body's energy source from carbohydrates to fats, which may help control seizures more effectively in some infants. Additionally, it can be administered orally or through a gastrostomy tube, offering flexibility for infants with different feeding needs.
What evidence suggests that the ketogenic diet might be an effective treatment for epileptic spasms?
Research has shown that the ketogenic diet, which participants in this trial will receive, can help reduce epileptic spasms in infants. Studies have found that at 3, 6, and 12 months after starting the diet, about 60% or more of infants experienced at least a 50% reduction in spasms. One study discovered that more than half of the infants became seizure-free within two weeks when the ketogenic diet was the first treatment used. This diet, high in fats and low in carbohydrates, has succeeded even when other treatments did not work. Overall, the ketogenic diet is a promising option for managing epileptic spasms, especially in challenging cases.12567
Are You a Good Fit for This Trial?
This trial is for infants with genetic seizure disorders, aimed at preventing epileptic spasms (ES) which can lead to developmental and cognitive issues. It's a small study of just 10 babies to see if starting them early on a ketogenic diet—a high-fat, low-carb/protein eating plan—is safe and doable.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the ketogenic diet starting within 6 weeks of enrollment, with adherence to EEG testing every 6 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment, including EEG compliance and safety outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Ketogenic Diet
Find a Clinic Near You
Who Is Running the Clinical Trial?
Heather Olson
Lead Sponsor
Boston Children's Hospital Translational Research Program (TRP) Pappendick Family Therapeutic Acceleration Award
Collaborator